• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Ibrutinib improves survival in refractory chronic lymphoid leukemia

byJon Liu
June 5, 2014
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Ibrutinib was superior to ofatumumab in a head-to-head trial in patients who have failed initial therapy for chronic lymphoid leukemia (CLL) and small lymphocytic leukemia (SLL). 

2. The benefit of progression-free survival for those on ibrutinib was preserved across all subgroups including common poor prognostic indicators (e.g. specific cytogenetic abnormalities). 

Evidence Rating Level: 1 (Excellent)       

Study Rundown: Molecular therapy is continually changing the approach to treatment of hematologic malignancies such as chronic lymphoid leukemia (CLL) and small lymphocytic leukemia (SLL). Outcomes from these malignancies are often guided by a short duration to response to first-line therapy and certain cytogenetic abnormalities. Ibrutinib, a Bruton’s tyrosine kinase inhibitor, is a new chemoimmunotherapy for CLL and SLL that interferes with signaling and downstream B-cell function.

This open-label, multi-centered, phase 3 trial randomized patients with CLL or SLL to treatment with ibrutinib or another indicated anti-CD20 agent, ofatumumab. Only patients who have failed first-line (or more) therapy for CLL or SLL were enrolled in this trial. Ibrutinib was superior to ofatumumab for progression-free survival and this benefit was preserved across all subgroups (which typically predict poor prognosis) including age, number of prior treatments, and specific cytogenetic abnormalities.

Overall, ibrutinib is a new and promising therapy (as measured by progression-free survival) for those with CLL or SLL who have failed prior therapies or have other poor prognostic indicators. After 4 months from the start of this trial, crossover from ofatumumab to ibrutinib was approved. Among baseline characteristics, patients in the ibrutinib group received a median of 3 prior treatments versus 2 in the ofatumumab group; therefore, those in the ibrutinib group may have been treated more aggressively prior to randomization. Whether the benefit of ibrutinib is also preserved in patients who are treatment-naive remains to be studied.

Click to read the study, published today in NEJM

RELATED REPORTS

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia

#VisualAbstract Adding uproleselan to chemotherapy in patients with relapsed or refractory acute myeloid leukemia was well-tolerated with high remission rates

In-Depth [randomized controlled trial]: This study randomized 391 patients (from the U.S., Australia, and seven European countries) to receive oral ibrutinib or an ofatumumab infusion protocol. In order to be enrolled, CLL and SLL patients had to have received at least one prior therapy and be deemed inappropriate for purine analogue treatment for various reasons. Baseline characteristics were well-matched between the two groups including age, gender, ECOG, various laboratory parameters, cytogenetics, and attempted previous therapies. The primary endpoint of median progression-free survival was not reached at 9.4 months follow-up for the ibrutinib group compared to 8.1 months for the ofatumumab group (hazard ratio, 0.22; P<0.001). A total of 57 patients from the ofatumumab group crossed over to receive ibrutinib after confirmed disease progression; however, the outcomes of these patients after crossover were not reported. Common non-hematologic adverse events in the ibrutinib group included diarrhea, fatigue, pyrexia and nausea. Treatment exposure was longer in the ibrutinib group with a median of 8.6 months compared to a median of 5.3 months in the ofatumumab group.

More from this author: Idelalisib plus rituximab improves progression-free survival in relapsed CLL, SSRI use during pregnancy not linked to increased risk of autism, Combo antifungal therapy most effective treatment for cryptococcal meningitis 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

 

Tags: Ibrutinibleukemia
Previous Post

Genetic and environmental factors linked with sagging eyelids

Next Post

Report argues hospitals may be unconstitutionally forced to accept public for no pay

RelatedReports

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia
StudyGraphics

#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia

November 27, 2021
#VisualAbstract Adding uproleselan to chemotherapy in patients with relapsed or refractory acute myeloid leukemia was well-tolerated with high remission rates
StudyGraphics

#VisualAbstract Adding uproleselan to chemotherapy in patients with relapsed or refractory acute myeloid leukemia was well-tolerated with high remission rates

September 30, 2021
#VisualAbstract Ibrutinib may be beneficial in heavily pretreated patients with classic and variant hairy cell leukemia
StudyGraphics

#VisualAbstract Ibrutinib may be beneficial in heavily pretreated patients with classic and variant hairy cell leukemia

July 8, 2021
Next Post
Patient transfers to trauma centers often unnecessary

Report argues hospitals may be unconstitutionally forced to accept public for no pay

Diabetic patients report improved vision after ranibizumab treatment

Steroid implant may improve diabetic macular edema

Hypercortisolemia in ICU patients is due to reduced cortisol metabolism, not increased production

Intraoperative PEEP levels may not affect post-operative pulmonary complications

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Methamphetamine use associated with cardiovascular disease in hospitalized patients
  • Management of uncomplicated urinary tract infections amongst women in the United States Military Health System highly concordant with guidelines
  • Gout flares associated with a transient increase in subsequent risk of cardiovascular events
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.